Literature DB >> 9271507

The physical exchange of factor VIII (FVIII) between von Willebrand factor and activated platelets and the effect of the FVIII B-domain on platelet binding.

X Li1, D A Gabriel.   

Abstract

Normal hemostasis proceeds through the assembly of coagulant complexes on a lipid surface derived from activated platelets. The activation complex assembly is governed by multiple factors including the binding constants (Kd) of the coagulant factors for the lipid surface. The formation of the tenase complex requires delivery of factor VIII (FVIII) to the activated lipid surface by von Willebrand factor (vWF). Using electrophoretic quasi-elastic light scattering (ELS), we have examined the interaction of FVIII in the presence and absence of vWF with both resting and activated gel-filtered human platelets. Resting platelets do not bind FVIII. Platelets activated by thrombin, epinephrine, or SFLLRN, but not ADP or collagen, bind unactivated FVIII if vWF is not present. In the absence of vWF, unactivated FVIII binds to activated platelets with a Kd of 10.4 nM. B-domain deleted FVIII binds to activated platelets with a Kd of 5.1 nM. Thrombin -activated FVIII (FVIIIa) binds to activated platelets with a Kd of 1.7 nM. The activation of FVIII while bound to the platelet surface can be monitored as a function of time. In the presence of vWF, binding of unactivated FVIII to activated platelets was inhibited, but not the binding of FVIIIa. Displacement of bound unactivated FVIII from the platelet surface occurs when vWF is added to the FVIII-platelet complex. The binding of FVIII to activated platelets is affected by the B-domain, the state of FVIII activation, and the presence of soluble vWF and proceeds as a multistep process. FVIII binding by activated platelets is not affected by platelet gpIIb/IIIa or by platelet vWF.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9271507     DOI: 10.1021/bi970052+

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.

Authors:  Krithika A Shetty; Matthew P Kosloski; Donald E Mager; Sathy V Balu-Iyer
Journal:  Biopharm Drug Dispos       Date:  2016-09-13       Impact factor: 1.627

2.  Kinetics of Factor X activation by the membrane-bound complex of Factor IXa and Factor VIIIa.

Authors:  Mikhail A Panteleev; Evgueni L Saenko; Natalya M Ananyeva; Fazoil I Ataullakhanov
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

3.  The factor VIII C1 domain contributes to platelet binding.

Authors:  Ting-Chang Hsu; Kathleen P Pratt; Arthur R Thompson
Journal:  Blood       Date:  2007-10-04       Impact factor: 22.113

4.  O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII.

Authors:  Razvan D Miclea; Vivek S Purohit; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2007-06-29       Impact factor: 4.009

5.  Soy phosphatidylinositol containing nanoparticle prolongs hemostatic activity of B-domain deleted factor VIII in hemophilia A mice.

Authors:  Krithika A Shetty; Matthew P Kosloski; Donald E Mager; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2014-04-02       Impact factor: 3.534

6.  Production of recombinant human factor VIII in different cell lines and the effect of human XBP1 co-expression.

Authors:  Mariana Campos-da-Paz; Christiane Silva Costa; Luana Salgado Quilici; Isabella de Carmo Simões; Cynthia Maria Kyaw; Andrea Queiroz Maranhão; Marcelo Macedo Brigido
Journal:  Mol Biotechnol       Date:  2008-06       Impact factor: 2.695

7.  Stable high-level expression of factor VIII in Chinese hamster ovary cells in improved elongation factor-1 alpha-based system.

Authors:  Nadezhda A Orlova; Sergey V Kovnir; Alexandre G Gabibov; Ivan I Vorobiev
Journal:  BMC Biotechnol       Date:  2017-03-24       Impact factor: 2.563

Review 8.  Coagulation Pathways in Neurological Diseases: Multiple Sclerosis.

Authors:  Nicole Ziliotto; Francesco Bernardi; Dejan Jakimovski; Robert Zivadinov
Journal:  Front Neurol       Date:  2019-04-24       Impact factor: 4.003

9.  Blood Clotting Factor VIII: From Evolution to Therapy.

Authors:  N A Orlova; S V Kovnir; I I Vorobiev; A G Gabibov; A I Vorobiev
Journal:  Acta Naturae       Date:  2013-04       Impact factor: 1.845

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.